Get the Stockscreener App
3.41
22.66%
0.63
Liminatus Pharma Inc stock is traded at $3.41, with a volume of 35.47M.
It is up +22.66% in the last 24 hours and down -41.00% over the past month.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
See More
Previous Close:
$2.78
Open:
$3.83
24h Volume:
35.47M
Relative Volume:
61.26
Market Cap:
$88.71M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-14.75%
1M Performance:
-41.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.09
$4.06
1-Week Range:
$2.53
$4.12
52-Week Range:
$2.53
$33.66
Liminatus Pharma Inc Stock (LIMN) Company Profile
Name
Liminatus Pharma Inc
Sector
Industry
Phone
213-273-5453
Address
6 CENTERPOINTE DR., LA PALMA
Compare LIMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
3.41 | 107.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Liminatus Pharma Inc Stock (LIMN) Latest News
Using R and stats models for Liminatus Pharma Inc. Equity Warrant forecastingPortfolio Gains Report & Long Hold Capital Preservation Plans - Newser
Bullish Candlestick Pattern Forms in Liminatus Pharma Inc. Equity Warrant2025 Dividend Review & Accurate Trade Setup Notifications - thegnnews.com
Using economic indicators to assess Liminatus Pharma Inc. Equity Warrant potential2025 Market Trends & Scalable Portfolio Growth Methods - Newser
Liminatus Pharma Inc. Equity Warrant stock chart pattern explainedJuly 2025 Sector Moves & Community Consensus Trade Alerts - Newser
Is Liminatus Pharma Inc. still worth holding after the dipQuarterly Profit Report & Risk Managed Investment Entry Signals - Newser
Will breakout in Liminatus Pharma Inc. Equity Warrant lead to full recoveryJuly 2025 Reactions & Safe Capital Growth Tips - Newser
Will Liminatus Pharma Inc. Equity Warrant see short term momentumRate Cut & High Return Trade Opportunity Guides - Newser
Reversal indicators forming on Liminatus Pharma Inc. Equity Warrant stockRate Cut & Real-Time Volume Analysis Alerts - Newser
What makes Liminatus Pharma Inc. stock price move sharplyGap Down & Breakout Confirmation Trade Signals - beatles.ru
Using data filters to optimize entry into Liminatus Pharma Inc.July 2025 PostEarnings & High Return Trade Opportunity Guides - Newser
Liminatus Pharma Inc. Equity Warrant stock retracement – recovery analysisBuy Signal & Weekly Breakout Opportunity Watchlist - Newser
Will Liminatus Pharma Inc. Equity Warrant price bounce be sustainable2025 Trading Recap & Reliable Volume Spike Trade Alerts - Newser
How to build a custom watchlist for Liminatus Pharma Inc.Dividend Hike & AI Driven Stock Reports - Newser
Real time pattern detection on Liminatus Pharma Inc. stockJuly 2025 Drop Watch & Capital Efficient Trade Techniques - Newser
Liminatus Pharma Inc. Equity Warrant stock trend forecastMarket Activity Summary & Consistent Profit Focused Trading Strategies - Newser
Can swing trading help recover from Liminatus Pharma Inc. Equity Warrant lossesDip Buying & Smart Allocation Stock Reports - Newser
Pattern recognition hints at Liminatus Pharma Inc. upsideEarnings Trend Report & Expert Approved Momentum Ideas - Newser
What’s next for Liminatus Pharma Inc. stock priceMarket Activity Summary & Weekly Watchlist for Consistent Profits - Newser
Is Liminatus Pharma Inc. Equity Warrant trending in predictive chart modelsIPO Watch & AI Driven Stock Reports - Newser
When is the best time to exit Liminatus Pharma Inc. Equity Warrant2025 Valuation Update & Daily Chart Pattern Signals - Newser
Is Liminatus Pharma Inc. Equity Warrant stock entering bullish territoryWeekly Investment Report & Free Growth Oriented Trading Recommendations - Newser
Applying sector rotation models to Liminatus Pharma Inc.Portfolio Return Summary & Real-Time Volume Analysis Alerts - Newser
Ranking Liminatus Pharma Inc. among high performing stocks via toolsJuly 2025 Trends & Low Risk Growth Stock Ideas - Newser
Liminatus Pharma Inc. stock volume spike explainedWeekly Profit Analysis & AI Optimized Trading Strategy Guides - Newser
Is Liminatus Pharma Inc. forming a reversal pattern2025 Buyback Activity & AI Enhanced Trading Alerts - Newser
Institutional scanner results for Liminatus Pharma Inc. Equity Warrant2025 Major Catalysts & Verified Momentum Stock Alerts - Newser
Liminatus Pharma stock gains on regaining compliance with Nasdaq - MSN
Liminatus Pharma Delays Quarterly Report Filing - MSN
Multi asset correlation models including Liminatus Pharma Inc.Trade Volume Summary & Growth Focused Investment Plans - Newser
Will Liminatus Pharma Inc. Equity Warrant benefit from macro trendsJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
What machine learning models say about Liminatus Pharma Inc.Dollar Strength & Community Driven Trade Alerts - Newser
Bollinger Band Squeeze Points to Volatility in Liminatus Pharma Inc.CEO Change & Short-Term High Return Strategies - 선데이타임즈
Liminatus Pharma Updates on CD47 Inhibitor IBA101 - MSN
Has Liminatus Pharma Inc. Equity Warrant formed a bullish divergenceJuly 2025 Patterns & Community Consensus Trade Alerts - Newser
Liminatus Pharma Inc. Stages Intraday Comeback — Trend Change2025 Price Action Summary & Consistent Income Trade Recommendations - beatles.ru
Combining price and volume data for Liminatus Pharma Inc. Equity WarrantJuly 2025 Movers & Daily Oversold Bounce Ideas - Newser
Liminatus Pharma Inc Stock (LIMN) Financials Data
There is no financial data for Liminatus Pharma Inc (LIMN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):